Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$15.34 -0.81 (-4.99%)
As of 11/16/2026

AVTE vs. NVAX, KLRA, NRIX, SLS, and NTLA

Should you buy Aerovate Therapeutics stock or one of its competitors? Aerovate Therapeutics's main competitors and comparable companies include Novavax (NVAX), Kailera Therapeutics (KLRA), Nurix Therapeutics (NRIX), SELLAS Life Sciences Group (SLS), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aerovate Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Aerovate Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -18.64%. Novavax's return on equity of -14.82% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax-18.64% -14.82% -7.55%
Aerovate Therapeutics N/A -90.19%-77.47%

Novavax has higher revenue and earnings than Aerovate Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.12B1.16$440.30M-$0.46N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Novavax presently has a consensus target price of $12.33, indicating a potential upside of 55.63%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.20
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Novavax had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Novavax and 0 mentions for Aerovate Therapeutics. Novavax's average media sentiment score of 0.56 beat Aerovate Therapeutics' score of 0.00 indicating that Novavax is being referred to more favorably in the media.

Company Overall Sentiment
Novavax Positive
Aerovate Therapeutics Neutral

Novavax has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Summary

Novavax beats Aerovate Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Kailera Therapeutics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Kailera Therapeutics and 0 mentions for Aerovate Therapeutics. Kailera Therapeutics' average media sentiment score of 0.69 beat Aerovate Therapeutics' score of 0.00 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Kailera Therapeutics Positive
Aerovate Therapeutics Neutral

Aerovate Therapeutics' return on equity of -90.19% beat Kailera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kailera TherapeuticsN/A -102.35% -38.58%
Aerovate Therapeutics N/A -90.19%-77.47%

Kailera Therapeutics presently has a consensus target price of $43.00, indicating a potential upside of 247.33%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kailera Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kailera TherapeuticsN/AN/A-$148.96M-$3.65 thousandN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Summary

Kailera Therapeutics beats Aerovate Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Nurix Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Nurix Therapeutics has a net margin of 42.01% compared to Aerovate Therapeutics' net margin of 0.00%. Nurix Therapeutics' return on equity of 49.34% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Nurix Therapeutics 42.01%49.34%38.61%

Aerovate Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Nurix Therapeutics$83.98M18.60-$264.46M$2.316.19

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Nurix Therapeutics has a consensus target price of $34.43, suggesting a potential upside of 140.76%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87

In the previous week, Nurix Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Nurix Therapeutics and 0 mentions for Aerovate Therapeutics. Nurix Therapeutics' average media sentiment score of 0.46 beat Aerovate Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Nurix Therapeutics Neutral

Summary

Nurix Therapeutics beats Aerovate Therapeutics on 12 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Aerovate Therapeutics (NASDAQ:AVTE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.20N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, SELLAS Life Sciences Group had 24 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 24 mentions for SELLAS Life Sciences Group and 0 mentions for Aerovate Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.64 beat Aerovate Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Overall Sentiment
SELLAS Life Sciences Group Positive
Aerovate Therapeutics Neutral

SELLAS Life Sciences Group has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential downside of 50.53%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe SELLAS Life Sciences Group is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SELLAS Life Sciences Group's return on equity of -33.96% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -33.96% -31.75%
Aerovate Therapeutics N/A -90.19%-77.47%

Summary

SELLAS Life Sciences Group beats Aerovate Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Intellia Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Intellia Therapeutics had 11 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 11 mentions for Intellia Therapeutics and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Intellia Therapeutics' score of -0.08 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Intellia Therapeutics Neutral

88.8% of Intellia Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Intellia Therapeutics has a consensus target price of $21.44, suggesting a potential upside of 119.61%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33

Aerovate Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -805.75%. Intellia Therapeutics' return on equity of -64.74% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Intellia Therapeutics -805.75%-64.74%-50.72%

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market.

Aerovate Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Intellia Therapeutics$67.67M20.25-$412.69M-$3.35N/A

Summary

Intellia Therapeutics beats Aerovate Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

MetricAerovate TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$444.49M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-5.1327.4232.3226.73
Price / SalesN/A16.068.565.71
Price / CashN/A22.9521.0121.90
Price / Book3.874.184.463.72
Net Income-$75.52M-$24.15M$3.52B$393.10M
7 Day Performance-1.70%-7.25%-5.47%-4.73%
1 Month Performance13.85%-5.98%-4.57%-7.14%
1 Year Performance43.32%-7.72%-1.79%-7.51%

Aerovate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$15.34
-5.0%
N/A+50.8%$444.49MN/AN/A20
NVAX
Novavax
1.9562 of 5 stars
$10.20
-6.3%
$12.33
+20.9%
+15.6%$1.80B$1.12BN/A749
KLRA
Kailera Therapeutics
2.2901 of 5 stars
$14.24
+3.9%
$43.00
+202.0%
N/A$1.78BN/AN/A145
NRIX
Nurix Therapeutics
3.6859 of 5 stars
$15.88
-1.6%
$34.43
+116.8%
+15.1%$1.76B$83.98M6.87357
SLS
SELLAS Life Sciences Group
0.415 of 5 stars
$8.37
-2.4%
$10.00
+19.5%
+422.4%$1.73BN/AN/A13

Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners